Human SLAMF7/CRACC/CD319 Protein
Catalog No: CD319-HF002
- Species
- Human
- Expression System
- HEK293
- Tag
- an mFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human SLAMF7/CRACC/CD319 Protein is expressed in HEK293 cells with an mFc (IgG1) tag at the C-terminus. It contains amino acid residues Ser23-Met226 (UniProt accession: Q9NQ25-1).
Product Details
- Molecular Aliases
- CD2 subset 1; CRACC; Novel Ly9; CD319; SLAMF7; CS1; 19A; FOAP-12;FOAP12
- Protein Length
- Ser23-Met226
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 48.8 kDa. Due to glycosylation, the protein migrates to 65-85 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 90% as determined by HPLC
- Endotoxin
- Less than 0.1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 24 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human SLAMF7 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human SLAMF7 is greater than 90% as determined by SEC-HPLC.
Immobilized Human SLAMF7, mFc Tag at 1μg/ml (100μl/Well). Dose response curve for Anti-SLAMF7 Antibody, hFc Tag with the EC50 of 15.7ng/ml determined by ELISA.
Background
CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family.Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response.
References
- Niels W. C. J. van de Donk, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma[J]. Blood, 2016, 127(6):681-695. Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.